spacer
home > ebr > autumn 2017 > revamping regulations
PUBLICATIONS
European Biopharmaceutical Review

Revamping Regulations

Stem cell products hold great promise for multiple clinical indications and are actively studied in clinical trials (1). However, many related safety features raise concerns and currently generate extensive and costly testing of the final product, if intended for clinical use. The regulatory expectations for stem cell testing for clinical studies, as well as marketing authorisation applications, are not entirely clear, up-to-date or detailed. Furthermore, differences between US and EU guidance, in this respect, hamper the current development of products for EU markets.

Risk Profiling

Stem cells used for therapeutic purposes include a wide variety of cells with different type differentiation capacities, spanning from restricted multipotent up to pluripotent stem cells (2). Hematopoietic stem cells have been widely used for ex vivo gene therapy of monogenic inherited diseases, and mesenchymal stem cells have been utilised – eg in treatment of Graft versus Host Disease – for more than a decade due to their immunomodulatory properties (3,4). Pluripotent stem cells, ie embryonic stem cells and induced pluripotent stem cells (iPSCs), are still in early clinical development, yet some clinical data are already available (5,6).

When considering possible risks of stem cells, several issues need to be considered, such as the donor (autologous versus allogeneic), characteristics of the cells, extent of manipulation, design of vectors for genetic modification, dose and the existing knowledge of the cell type/product to be used. One of the main concerns related to stem cell products is tumourigenicity. For pluripotent stem cells, teratoma formation is part of their natural characteristics, which calls for thorough control of the cell differentiation status before clinical use.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Paula Salmikangas, Director for Biopharmaceuticals and ATMPs, NDA Advisory Board, is a clinical biochemist by original training with a PhD in muscle cell biology. Since 2006, she has been an Adjunct Professor of Biochemistry for the University of Helsinki, Finland. Paula joined NDA in 2017, has served as a member of the EMA Committee for Advanced Therapies (CAT) from 2009 to 2017 and has been the Chair of the CAT 2014-2017. Her main areas of expertise are biological medicinal products, especially ATMPs, chemistry, manufacturing and controls aspects of biopharmaceuticals.
spacer
Dr Paula Salmikangas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement